Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NDX 1017

Drug Profile

NDX 1017

Alternative Names: NDX1017

Latest Information Update: 13 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator M3 Biotechnology
  • Developer Athira Pharma
  • Class Antidementias; Small molecules
  • Mechanism of Action Hepatocyte growth factor stimulants; Proto oncogene protein c met stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Parkinson's disease

Most Recent Events

  • 09 Dec 2019 Preclinical trials in Parkinson's disease in USA (SC)
  • 05 Sep 2019 Athira Pharma completes a phase I trial in Alzheimer's disease (In adults, In the elderly) in USA and France (NCT03298672)
  • 17 Jul 2019 Interim adverse events and pharmcodynamic data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2019 (AAIC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top